DDReg is thrilled to announce its participation as exhibitors at BIO and DIA Global 2024 to provide biotech and ...

The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.

First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.

SpliceCore is Envisagenics' proprietary AI/ML platform that enables the translation of vast amounts of RNA sequencing data into novel therapeutics. SpliceCore's versatility extends to both the ...

Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.

Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims could eventually compete with market-leading medicines from Novo Nordisk and ...

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.

Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.